Logo image of ALVAL.PA

VALBIOTIS SA (ALVAL.PA) Stock Fundamental Analysis

EPA:ALVAL - FR0013254851 - Common Stock

0.797 EUR
-0.03 (-3.74%)
Last: 9/4/2025, 7:00:00 PM
Fundamental Rating

2

ALVAL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 74 industry peers in the Biotechnology industry. The financial health of ALVAL is average, but there are quite some concerns on its profitability. ALVAL is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ALVAL had negative earnings in the past year.
ALVAL had a negative operating cash flow in the past year.
ALVAL had negative earnings in each of the past 5 years.
ALVAL had negative operating cash flow in 4 of the past 5 years.
ALVAL.PA Yearly Net Income VS EBIT VS OCF VS FCFALVAL.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M

1.2 Ratios

ALVAL has a worse Return On Assets (-51.13%) than 64.86% of its industry peers.
The Return On Equity of ALVAL (-96.69%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -51.13%
ROE -96.69%
ROIC N/A
ROA(3y)-39.5%
ROA(5y)-33.42%
ROE(3y)-75.49%
ROE(5y)-68.14%
ROIC(3y)N/A
ROIC(5y)N/A
ALVAL.PA Yearly ROA, ROE, ROICALVAL.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

ALVAL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALVAL.PA Yearly Profit, Operating, Gross MarginsALVAL.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

4

2. Health

2.1 Basic Checks

ALVAL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALVAL has about the same amount of shares outstanding.
The number of shares outstanding for ALVAL has been increased compared to 5 years ago.
The debt/assets ratio for ALVAL is higher compared to a year ago.
ALVAL.PA Yearly Shares OutstandingALVAL.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
ALVAL.PA Yearly Total Debt VS Total AssetsALVAL.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

ALVAL has an Altman-Z score of 1.43. This is a bad value and indicates that ALVAL is not financially healthy and even has some risk of bankruptcy.
ALVAL's Altman-Z score of 1.43 is fine compared to the rest of the industry. ALVAL outperforms 62.16% of its industry peers.
A Debt/Equity ratio of 0.34 indicates that ALVAL is not too dependend on debt financing.
ALVAL's Debt to Equity ratio of 0.34 is in line compared to the rest of the industry. ALVAL outperforms 58.11% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Altman-Z 1.43
ROIC/WACCN/A
WACC6.9%
ALVAL.PA Yearly LT Debt VS Equity VS FCFALVAL.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

ALVAL has a Current Ratio of 3.04. This indicates that ALVAL is financially healthy and has no problem in meeting its short term obligations.
ALVAL has a better Current ratio (3.04) than 67.57% of its industry peers.
A Quick Ratio of 2.66 indicates that ALVAL has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.66, ALVAL is in the better half of the industry, outperforming 67.57% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.04
Quick Ratio 2.66
ALVAL.PA Yearly Current Assets VS Current LiabilitesALVAL.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

5

3. Growth

3.1 Past

ALVAL shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.43%.
Looking at the last year, ALVAL shows a very negative growth in Revenue. The Revenue has decreased by -96.30% in the last year.
The Revenue has been growing by 13.97% on average over the past years. This is quite good.
EPS 1Y (TTM)-6.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.15%
Revenue 1Y (TTM)-96.3%
Revenue growth 3Y-16.26%
Revenue growth 5Y13.97%
Sales Q2Q%-71.54%

3.2 Future

The Earnings Per Share is expected to grow by 25.84% on average over the next years. This is a very strong growth
ALVAL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 361.83% yearly.
EPS Next Y39.26%
EPS Next 2Y22.93%
EPS Next 3Y25.84%
EPS Next 5YN/A
Revenue Next Year850%
Revenue Next 2Y565.23%
Revenue Next 3Y361.83%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALVAL.PA Yearly Revenue VS EstimatesALVAL.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5M 10M 15M 20M
ALVAL.PA Yearly EPS VS EstimatesALVAL.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALVAL. In the last year negative earnings were reported.
Also next year ALVAL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALVAL.PA Price Earnings VS Forward Price EarningsALVAL.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALVAL.PA Per share dataALVAL.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

ALVAL's earnings are expected to grow with 25.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.93%
EPS Next 3Y25.84%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALVAL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VALBIOTIS SA

EPA:ALVAL (9/4/2025, 7:00:00 PM)

0.797

-0.03 (-3.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-25 2025-04-25/amc
Earnings (Next)10-27 2025-10-27
Inst Owners2.25%
Inst Owner ChangeN/A
Ins Owners4.45%
Ins Owner ChangeN/A
Market Cap18.89M
Analysts85.45
Price Target3.35 (320.33%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-8.78%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)17.64%
EPS NY rev (3m)17.64%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-30.92%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 107.94
P/FCF N/A
P/OCF N/A
P/B 1.82
P/tB 2.04
EV/EBITDA N/A
EPS(TTM)-0.63
EYN/A
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS0.01
BVpS0.44
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -51.13%
ROE -96.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.5%
ROA(5y)-33.42%
ROE(3y)-75.49%
ROE(5y)-68.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score0
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 44.46%
Cap/Sales 149.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.04
Quick Ratio 2.66
Altman-Z 1.43
F-Score0
WACC6.9%
ROIC/WACCN/A
Cap/Depr(3y)37.28%
Cap/Depr(5y)37.7%
Cap/Sales(3y)63.68%
Cap/Sales(5y)68.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.15%
EPS Next Y39.26%
EPS Next 2Y22.93%
EPS Next 3Y25.84%
EPS Next 5YN/A
Revenue 1Y (TTM)-96.3%
Revenue growth 3Y-16.26%
Revenue growth 5Y13.97%
Sales Q2Q%-71.54%
Revenue Next Year850%
Revenue Next 2Y565.23%
Revenue Next 3Y361.83%
Revenue Next 5YN/A
EBIT growth 1Y-45.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year27.6%
EBIT Next 3Y18.82%
EBIT Next 5Y25.3%
FCF growth 1Y-42.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-43.23%
OCF growth 3YN/A
OCF growth 5YN/A